The Hydration Pharmaceuticals Company Limited Stock
Stocks
HPC
AU0000187957
Pharmaceuticals
OTC Markets Traded|
Market Closed -
Australian S.E.
23:34:48 2026-11-17 EST
|
5-day change | 1st Jan Change | ||
| 0.003000 AUD | 0.00% |
|
0.00% | -40.00% |
| Market Cap | 1.08M 987K 909K 827K 1.55M 100M 1.63M 11.07M 4.4M 54.8M 4.06M 3.98M 172M | P/E 2024 |
4.69x | P/E 2025 | -0.45x |
|---|---|---|---|---|---|
| Enterprise Value | -35.16K -32.03K -29.51K -26.85K -50.36K -3.26M -52.93K -359K -143K -1.78M -132K -129K -5.58M | EV / Sales 2024 |
0.06x | EV / Sales 2025 | 0.13x |
| Free-Float |
42.04% | Yield 2024 * |
-
| Yield 2025 | - |
| 3 months | -40.00% | ||
| Current year | -40.00% |
| 1 week | 0 | 0 | |
| 1 month | 0 | 0 | |
| Current year | 0 | 0.01 | |
| 1 year | 0 | 0.01 | |
| 3 years | 0 | 0.04 | |
| 5 years | 0 | 0.4 | |
| 10 years | 0 | 0.4 |
| Manager | Title | Age | Since |
|---|---|---|---|
Emily Lease
PRN | Corporate Officer/Principal | - | 2026-06-14 |
Victoria Nadalin
SEC | Corporate Secretary | - | 2023-02-07 |
| Director | Title | Age | Since |
|---|---|---|---|
Margaret Hardin
BRD | Director/Board Member | 53 | 2022-02-07 |
Nicholas Berry
CHM | Chairman | - | 2026-06-15 |
| Director/Board Member | - | 2026-06-15 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 10/4/23 | Free | Chairman | 500,000 | 0.2112% | ||
| 10/4/23 | Buy | Director | 333,333 | 0.1408% | ||
| 10/4/23 | Free | Director | 166,667 | 0.0704% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
| 0.00% | 0.00% | -50.00% | -90.91% | 1.07M | ||
| -0.30% | -6.68% | +27.12% | +127.32% | 1,200B | ||
| +1.25% | -5.35% | +32.65% | +78.98% | 651B | ||
| +0.94% | -2.99% | +21.13% | +106.30% | 506B | ||
| -0.60% | -1.95% | +25.73% | +67.00% | 377B | ||
| +0.69% | -9.50% | +36.78% | +30.83% | 330B | ||
| +0.41% | -4.70% | +24.18% | +50.18% | 288B | ||
| +0.81% | -4.08% | -2.95% | +31.59% | 272B | ||
| -0.15% | -6.45% | +29.06% | +65.76% | 236B | ||
| -0.06% | -0.98% | +31.42% | +122.83% | 206B | ||
| Average | +0.30% | -4.28% | +17.51% | +58.99% | 407B | |
| Weighted average by Cap. | +0.30% | -5.19% | +26.02% | +87.88% |
| 2024 | 2025 | |
|---|---|---|
| Net sales | 3.2M 2.92M 2.69M 2.45M 4.59M 297M 4.82M 32.74M 13.01M 162M 12.02M 11.77M 509M | 2.47M 2.25M 2.07M 1.89M 3.54M 229M 3.72M 25.25M 10.03M 125M 9.27M 9.08M 392M |
| Net income | 2.67M 2.43M 2.24M 2.04M 3.82M 247M 4.02M 27.25M 10.83M 135M 10.01M 9.8M 423M | -2.86M -2.61M -2.4M -2.18M -4.1M -265M -4.31M -29.22M -11.61M -145M -10.73M -10.51M -454M |
| Net Debt | -3.22M -2.93M -2.7M -2.46M -4.61M -298M -4.84M -32.85M -13.06M -163M -12.07M -11.81M -511M | -1.12M -1.02M -939K -854K -1.6M -104M -1.68M -11.43M -4.54M -56.58M -4.2M -4.11M -178M |
Employees
-
Sector
Pharmaceuticals
| Date | Price | Change | Volume |
|---|
- Stock Market
- Stocks
- HPC Stock
Select your edition
All financial news and data tailored to specific country editions
















